Australia's Mayne Pharma rises after settling patent litigation with India's Sun Pharma

Mayne Pharma

30/09/2026 05:15

** Shares of Mayne Pharma MYX.AX rise as much as 2.1% to A$2.890
     ** Speciality pharma co agrees to settle US patent litigation relating to IMVEXXY with India's Sun Pharma SUN.NS and the associated US Food and Drug Administration Orange Book patents
** MYX filed lawsuit in July 2024 after a notification indicated Sun Pharma submitted an abbreviated new drug application to FDA seeking approval to market a generic version of IMVEXXY, a vaginal insert aimed at reducing pain during sexual intercourse after menopause
** Settlement provides an agreed pathway for potential future entry of a Sun Pharma generic product on October 21, 2032, or earlier under certain circumstances, subject to court approval of settlement terms - MYX adds
** The settlement does not include any financial payment or upfront monetary consideration between the parties 
     ** YTD, stock down 7.7%

 (Reporting by Tejas Harish in Bengaluru)
 ((tejas.harish@thomsonreuters.com;))